|

Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

RECRUITINGN/ASponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Actively Recruiting
PhaseN/A
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
Started2023-11-11
Est. completion2030-12-31
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06189183

Summary

The purpose of this study is to evaluate the efficiency and toxicity of adjuvant hypofractionation radiotherapy for thymic epithelial tumours after complete resection.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Thymoma and Thymic carcinoma confirmed by histology or cytology
* R0 resection (complete resection)
* stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas.
* Karnofsky performance status(KPS) 80, 90 or 100.
* Having sufficient Pulmonary function, renal function and liver function. Neutrophile granulocyte count\>1.5×109 /L, platelet count\>80×109 /L, hemoglobin ≥10g/dL.

Exclusion Criteria:

* Prior thoracic radiotherapy.
* Uncontrolled Comorbidities.
* Pregnant or nursing mother.
* Pneumonia

Conditions2

CancerThymus Neoplasms

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.